Nathalie A. Feeley

Nathalie A. Feeley

Auto-generated profile, based on publicly available information

Nathalie A. Feeley

Institute of Genetics and Cancer University of Edinburgh Edinburgh UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
ACAlex J. Cornish
Alex J. Cornish
AGAndreas Gruber
Andreas Gruber
BKBen Kinnersley
Ben Kinnersley
DCDaniel Chubb
Daniel Chubb
AFAnna Frangou
Anna Frangou
Richard HoulstonRichard Houlston
Richard Houlston
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2–9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichiacolipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11–13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care.

15 October 2025 in Cancer Research
Verified
Journal Article
Open access
MGMeritxell Brunet Guasch
Meritxell Brunet Guasch
NFNathalie A. Feeley
Nathalie A. Feeley
ISIgnacio Soriano
Ignacio Soriano
STSteve Thorn
Steve Thorn
ITIan P.M. Tomlinson
Ian P.M. Tomlinson
TATibor Antal
Tibor Antal
Dysregulation of the tumor suppressor gene adenomatous polyposis coli (APC) is a canonical step in colorectal cancer development by promoting activation of the WNT/β-catenin pathway. Curiously, most colorectal tumors carry biallelic mutations that result in only partial loss of APC function, suggesting that a “just-right” level of APC inactivation, and hence WNT signaling, provides the optimal conditions for tumorigenesis. Mutational processes act variably across the APC gene, which could contribute to the bias against complete APC inactivation. In this study, we propose a mathematical model to quantify the tumorigenic effect of biallelic APC genotypes, controlling for somatic mutational processes. Analysis of sequence data from >2,500 colorectal cancers showed that APC genotypes resulting in partial protein function confer about 50 times higher probability of progressing to cancer compared with complete APC inactivation. The optimal inactivation level varied with anatomic location and additional mutations of WNT pathway regulators. Assessment of the regulatory effects of secondary alterations in WNT drivers in combination with APC in vivo provided evidence that AMER1 mutations increase WNT activity in tumors with suboptimal APC genotypes. The fitness landscape of APC inactivation was consistent across microsatellite unstable and polymerase epsilon–deficient colorectal cancers and tumors in patients with familial adenomatous polyposis. Together, these findings suggest a general “just-right” optimum for APC inactivation and WNT signaling, pointing to WNT hyperactivation as a potential vulnerability in cancer. Significance: Mathematical modeling of tumor development with different APC genotypes substantiates the “just-right” APC inactivation model and suggests alterations in secondary WNT regulators enhance WNT activity in colorectal cancers with suboptimal APC genotypes. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

17 June 2026
Verified
Other
Open access
MGMeritxell Brunet Guasch
Meritxell Brunet Guasch
NFNathalie A. Feeley
Nathalie A. Feeley
ISIgnacio Soriano
Ignacio Soriano
STSteve Thorn
Steve Thorn
ITIan P.M. Tomlinson
Ian P.M. Tomlinson
TATibor Antal
Tibor Antal
Dysregulation of the tumor suppressor gene adenomatous polyposis coli (APC) is a canonical step in colorectal cancer development by promoting activation of the WNT/β-catenin pathway. Curiously, most colorectal tumors carry biallelic mutations that result in only partial loss of APC function, suggesting that a “just-right” level of APC inactivation, and hence WNT signaling, provides the optimal conditions for tumorigenesis. Mutational processes act variably across the APC gene, which could contribute to the bias against complete APC inactivation. In this study, we propose a mathematical model to quantify the tumorigenic effect of biallelic APC genotypes, controlling for somatic mutational processes. Analysis of sequence data from >2,500 colorectal cancers showed that APC genotypes resulting in partial protein function confer about 50 times higher probability of progressing to cancer compared with complete APC inactivation. The optimal inactivation level varied with anatomic location and additional mutations of WNT pathway regulators. Assessment of the regulatory effects of secondary alterations in WNT drivers in combination with APC in vivo provided evidence that AMER1 mutations increase WNT activity in tumors with suboptimal APC genotypes. The fitness landscape of APC inactivation was consistent across microsatellite unstable and polymerase epsilon–deficient colorectal cancers and tumors in patients with familial adenomatous polyposis. Together, these findings suggest a general “just-right” optimum for APC inactivation and WNT signaling, pointing to WNT hyperactivation as a potential vulnerability in cancer.Significance:Mathematical modeling of tumor development with different APC genotypes substantiates the “just-right” APC inactivation model and suggests alterations in secondary WNT regulators enhance WNT activity in colorectal cancers with suboptimal APC genotypes.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.

17 June 2026
Verified
Other
Open access
MGMeritxell Brunet Guasch
Meritxell Brunet Guasch
NFNathalie A. Feeley
Nathalie A. Feeley
ISIgnacio Soriano
Ignacio Soriano
STSteve Thorn
Steve Thorn
ITIan P.M. Tomlinson
Ian P.M. Tomlinson
TATibor Antal
Tibor Antal

17 June 2026
Verified
Other
Open access
MGMeritxell Brunet Guasch
Meritxell Brunet Guasch
NFNathalie A. Feeley
Nathalie A. Feeley
ISIgnacio Soriano
Ignacio Soriano
STSteve Thorn
Steve Thorn
ITIan P.M. Tomlinson
Ian P.M. Tomlinson
TATibor Antal
Tibor Antal
Signature correction in hypermutant CRCs

17 June 2026
Verified
Other
Open access
MGMeritxell Brunet Guasch
Meritxell Brunet Guasch
NFNathalie A. Feeley
Nathalie A. Feeley
ISIgnacio Soriano
Ignacio Soriano
STSteve Thorn
Steve Thorn
ITIan P.M. Tomlinson
Ian P.M. Tomlinson
TATibor Antal
Tibor Antal
“Just-right” in patients with FAP. A–D, The distribution of the APC somatic hit in tumors of patients with FAP with germline mutations in different regions. Points indicate the observed distribution in patients with FAP from different studies (11, 12, 22), which collected 93 adenoma, 86 cancer, and 55 adenoma samples from 53, 23, and 18 patients with FAP, respectively. The line indicates the expected distribution calculated using the mutation and cancer progression probabilities estimated from healthy crypts and sporadic colorectal cancer data, with shaded regions for a conservative 95% CI, obtained by performing multinomial simulations with the number of trials given by the maximal number of patients across the studies in each germline group.